Authors
Latest:
Looking Toward the Future Management of Non–Small Cell Lung CancerClosing out their discussion on non–small cell lung cancer, panelists share their expectations for future improvements in care.
Latest:
Dr. Van Rhee on the Clinical Implications of CAR T-Cell Therapy in Relapsed/Refractory MyelomaFrits van Rhee, MD, PhD, discusses the clinical implications of CAR T-cell therapy for patients with relapsed/refractory multiple myeloma.
Latest:
Navigating a “Sea Change” in Frontline Urothelial Carcinoma TreatmentDavid H. Aggen, MD, PhD, details the evolving landscape of treating patients with urothelial carcinoma.
Latest:
Dr. Janakiram on Future Targets and Strategies for CAR T-cell Therapy in MyelomaMurali Janakiram, MD, MS, discusses future targets and research strategies for CAR T-cell therapy in multiple myeloma.
Latest:
Dr. Chauncey on Isatuximab Combinations in Multiple MyelomaThomas R. Chauncey, MD, PhD, discusses the phase 3 ICARIA-MM trial and IKEMA trials with isatuximab-irfc combinations in patients with relapsed or refractory multiple myeloma.
Latest:
Dr. Voorwerk on Rationale for Atezolizumab/Carboplatin in Metastatic Lobular Breast CancerLeonie Voorwerk, discusses the rationale for examining the combination of atezolizumab plus carboplatin in patients with metastatic lobular breast cancer.
Latest:
Board Review Resources 2024Drs Armstrong and Tawagi discuss the board review plans they followed in the months leading up to their hematology and oncology board exams.
Latest:
Intensification With Apalutamide/ADT Improves PSA PFS in Biochemically Recurrent Prostate CancerApalutamide/ADT maintains quality of life, demonstrates improved PSA progression-free survival in recurrent prostate cancer according to PRESTO trial.
Latest:
Understanding Lynch Syndrome and Associated Cancer Risk: Future Preventive ConsiderationsIn this sixth episode of OncChats: Understanding Lynch Syndrome and Cancer Risk, Fay Kastrinos, MD, MPH, shares future considerations for optimizing the identification of Lynch syndrome and other efforts underway to prevent colorectal cancer in those who have this condition.
Latest:
Dr Graham on the Evaluation of RAGE Inhibition for Therapy-Related Cardiotoxicity in Breast CancerDeena Mary Atieh Graham, MD, discusses a pilot study evaluating RAGE inhibition to reduce therapy-related cardiotoxicity in early-stage breast cancer.
Latest:
Dr Berkenstock on ADC-Related Ocular Toxicities in Cervical and Ovarian CancersMeghan K. Berkenstock, MD, discusses common ocular toxicities associated with the use of novel antibody-drug conjugates, and the subsequent development of mitigation strategies for these treatment-related adverse effects in gynecologic cancers.
Latest:
EGFR+ NSCLC: Advice for Community OncologistsA panel of experts in thoracic oncology concludes the discussion by emphasizing the importance of conducting reflex molecular testing, considering systemic therapy in all patients, and utilizing shared decision-making models.
Latest:
Future Research Directions in ALK+ and ROS1+ NSCLCGregory J. Riely, MD, PhD, and Benjamin Besse, MD, discuss unmet needs and future research directions in ALK-positive and ROS1-positive NSCLC.
Latest:
Antibody-Drug Conjugates Carve Out Space in Urothelial Carcinoma LandscapeMonoclonal antibodies have played a key role in the development of personalized oncology and have proven antitumor activity through multiple mechanisms, including direct transmembrane signaling leading to apoptosis, complement mediated cytotoxicity, antibody-dependent cellular cytotoxicity, and inhibiting tumor vasculature and stroma.
Latest:
Dr Leighl on Patient Satisfaction and Resource Utilization From PALOMA-3 in NSCLCNatasha B. Leighl, MD, BSc, MMSc, discusses patient satisfaction and resource utilization results from the phase 3 PALOMA-3 study.
Latest:
Dr Adjei on the Rationale for Opportunistic Salpingectomy for Ovarian Cancer PreventionNaomi Adjei, MD, MPH, MSEd, discusses an analysis of the cost-effectiveness of opportunistic salpingectomy for the primary prevention of ovarian cancer.
Latest:
Dr. Talati on Rationale for Collecting Real-World Data on Venetoclax/HMA Combos in AMLChetasi Talati, MD, discusses the design of a chart review study with venetoclax and hypomethylating agents in older patients with newly-diagnosed acute myeloid leukemia.
Latest:
2024 Outlook on Cancer Care: Striving to Overcome the ChallengesAlthough novel therapies have improved cancer care, cancer diagnoses have increased, with more than 2 million new cases estimated for 2024.
Latest:
Dr Bryant on the Influence of Germline DNA Repair Mutations on Therapeutic Development in PDACJohn M. Bryant, MD, discusses how identifying germline DNA repair mutations may impact the development of targeted therapy development in PDAC.
Latest:
Dr. D'Ambrosio on the Rationale of Accelerated Partial Breast Irradiation in HR+ Breast CancerDavid D'Ambrosio, MD, discusses the benefit of utilizing adjuvant accelerated partial breast irradiation, as well as a phase 2 trial investigating robotic stereotactic adjuvant accelerated partial breast irradiation for hormone receptor–positive, postmenopausal, early-stage breast cancer.
Latest:
Dr Doger de Spéville on Key Efficacy Findings From Part C of TACTI-002 in HNSCCBernard Doger de Spéville, MD, PhD, discusses key findings from part C of the phase 2 TACTI-002 trial of eftilagimod alpha plus pembrolizumab as second-line treatment for patients with head and neck squamous cell carcinoma.
Latest:
Dr Sidana on CAR T-cell Therapy in Patients With R/R Myeloma and Renal ImpairmentSurbhi Sidana, MD, discusses the unmet needs for patients with relapsed/refractory multiple myeloma who could be candidates for CAR T-cell therapy but have impaired renal function, and how clinical trials for these therapies have excluded this subset of patients.
Latest:
Assessing Bleeding Disorders: Keys for Hem/Onc FellowsMichelle Chi, MD and Jennifer R. Green, MD, share practical points for trainees to approach the initial evaluation for a bleeding-disorder patient.
Latest:
Dr Kalemkerian on Unmet Needs With the Use of Chemoimmunotherapy in ES-SCLCGregory Peter Kalemkerian, MD, discusses the unmet needs associated with the investigation of combination chemoimmunotherapy in the frontline treatment of patients with extensive-stage small cell lung cancer.
Latest:
OncLive Peer Exchange on Allo-HSCT: Conclusion of DiscussionThe expert panel recaps and synthesizes key points and conclusions from each presentation and discussion over the course of the program.
Latest:
Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLCKersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.
Latest:
Dr. Kroener on Utilizing Embryo Cryopreservation in Breast CancerLindsay L. Kroener, MD, discusses fertility preservation in patients with breast cancer.
Latest:
Dr. Shah on the Significance of PARP Inhibitors in Ovarian CancerPayal D. Shah, MD, discusses the significance of the emergence of PARP inhibitors in ovarian cancer.
Latest:
Dr. Pegram on the Evolving Treatment Landscape in HER2+ Breast CancerMark Pegram, MD, discusses the evolving treatment landscape of HER2-positive breast cancer.
Latest:
Dr Dasari on Salvage Treatment Considerations for Unresectable Metastatic CRCArvind N. Dasari, MD, MS, discusses later-line treatment considerations for patients with unresectable metastatic colorectal cancer.
.jpg?fit=crop&auto=format)
